Profund Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Profund Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$239K	Buy	41,133 +2,186	+6%	+$14.5K	0.01%	916
2025 Q4	$306K	Buy	38,947 +12,383	+47%	+$97.5K	0.01%	859
2025 Q3	$216K	Sell	26,564 -15,516	-37%	-$103K	0.01%	937
2025 Q2	$197K	Buy	42,080 +21,888	+108%	+$100K	0.01%	911
2025 Q1	$111K	Sell	20,192 -2,777	-12%	-$11.2K	﹤0.01%	945
2024 Q4	$77.9K	Buy	22,969 +227	+1%	+$730	﹤0.01%	1084
2024 Q3	$64.8K	Sell	22,742 -1,978	-8%	-$5.08K	﹤0.01%	1125
2024 Q2	$55.6K	Sell	24,720 -3,655	-13%	-$7.37K	﹤0.01%	1065
2024 Q1	$62.7K	Buy	+28,375	New	+$73.4K	﹤0.01%	1140

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT)

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return